Role of high-affinity HLA-DP specific CLIP-derived peptides in beryllium binding to the HLA-DPGlu69 berylliosis-associated molecules and presentation to beryllium-sensitized T cells

Immunology

Volumn 128, Issue 1 PART 2, 2009, Pages

  Amicosante, Massimo ^a,b   Berretta, Floriana ^b   Dweik, Raed ^c   Saltini, Cesare ^b  

^a Department of Internal Medicine ^*  (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antigen presentation; Berylliosis; Beryllium; CLIP; Human leucocyte antigen; Human leucocyte antigen DP; Immunogenetic; Peptide based therapy; T cells

Indexed keywords

BERYLLIUM; GAMMA INTERFERON; HLA DP ANTIGEN; MONOCLONAL ANTIBODY; PEPTIDE DERIVATIVE; PROTEIN CLIP; UNCLASSIFIED DRUG;

ADULT; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; BERYLLIOSIS; BINDING AFFINITY; BINDING COMPETITION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MALE; METAL BINDING; MOLECULAR MODEL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADULT; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; BERYLLIOSIS; BERYLLIUM; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DP ANTIGENS; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 68249138316     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2008.03000.x     Document Type: Article

References (30)

1. Saltini C, Kirby M, Trapnell BC, Tamura N, Crystal RG. Biased accumulation of T lymphocytes with "memory"-type CD45 leukocyte common antigen gene expression on the epithelial surface of the human lung. J Exp Med 1990 171 : 1123 30.
2. Saltini C, Winestock K, Kirby M, Pinkston P, Crystal RG. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med 1989 320 : 1103 9.
3. Fontenot AP, Canavera SJ, Gharavi L, Newman LS, Kotzin BL. Target organ localization of memory CD4(+) T cells in patients with chronic beryllium disease. J Clin Invest 2002 110 : 1473 82.
4. Kreiss K, Miller F, Newman L, Ojo-Amaize EA, Rossman M, Saltini C. Chronic beryllium disease. From the workplace to cellular immunology, molecular immunogenetics, and back. Clin Immunol Immunopath 1994 71 : 123 9.
5. Richeldi L, Sorrentino R, Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science 1993 262 : 242 4.
6. Richeldi L, Kreiss K, Mroz MM, Zhen B, Tartoni P, Saltini C. Interaction of genetic and exposure factors in the prevalence of berylliosis. Am J Ind Med 1997 32 : 337 40.
7. Wang Z, White PS, Petrovic M et al. Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. J Immunol 1999 163 : 1647 53.
8. Saltini C, Richeldi L, Losi M et al. Major histocompatibility locus genetic markers of beryllium sensitization and disease. Eur Respir J 2001 18 : 677 84.
9. Wang Z, Farris GM, Newman LS, Shou Y, Maier LA, Smith HN. Beryllium sensitivity is linked to HLA-DP genotype. Toxicology 2001 165 : 27 38.
10. Rossman MD, Stubbs J, Lee CW, Argyris E, Magira E, Monos D. Human leukocyte antigen Class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity. Am J Respir Crit Care Med 2002 165 : 788 94.
11. Maier LA, McGrath DS, Sato H et al. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J Immunol 2003 171 : 6910 8.
12. McCanlies EC, Ensey JS, Schuler CR, Kreiss K, Weston A. The association between HLA-DPB1Glu69 and chronic beryllium disease and beryllium sensitization. Am J Ind Med 2004 46 : 95 103.
13. Amicosante M, Berretta F, Rossman M et al. Identification of HLA-DRPhebeta47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGlubeta69. Respir Res 2005 6 : 94.
14. Lombardi G, Germain C, Uren J et al. HLA-DP allele-specific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease. J Immunol 2001 166 : 3549 55.
15. + T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. Proc Natl Acad Sci USA 2000 97 : 12717 22.
16. Amicosante M, Deubner D, Saltini C. Role of the berylliosis-associated HLA-DPGlu69 supratypic variant in determining the response to beryllium in a blood T-cells beryllium-stimulated proliferation test. Sarcoidosis Vasc Diffuse Lung Dis 2005 22 : 175 9.
17. + T cells is dependent on a single amino acid residue of the MHC class II beta-chain. J Immunol 2005 175 : 7029 37.
18. Amicosante M, Sanarico N, Berretta F et al. Beryllium binding to HLA-DP molecule carrying the marker of susceptibility to berylliosis glutamate beta 69. Hum Immunol 2001 62 : 686 93.
19. Castelli FA, Buhot C, Sanson A et al. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J Immunol 2002 169 : 6928 34.
20. Berretta F, Butler RH, Diaz G et al. Detailed analysis of the effects of Glu/Lys beta69 human leukocyte antigen-DP polymorphism on peptide-binding specificity. Tissue Antigens 2003 62 : 459 71.
21. Keizer TS, Sauer NN, McCleskey TM. Beryllium binding at neutral pH: the importance of the Be-O-Be motif. J Inorg Biochem 2005 99 : 1174 81.
22. Diaz G, Amicosante M, Jaraquemada D et al. Functional analysis of HLA-DP polymorphism: a crucial role for DPbeta residues 9, 11, 35, 55, 56, 69 and 84-87 in T cell allorecognition and peptide binding. Int Immunol 2003 15 : 565 76.
23. Diaz G, Canas B, Vazquez J, Nombela C, Arroyo J. Characterization of natural peptide ligands from HLA-DP2: new insights into HLA-DP peptide-binding motifs. Immunogenetics 2005 56 : 754 9.
24. ++ reactive human T cell clone. J Exp Med 2003 197 : 567 74.
25. Gamerdinger K, Moulon C, Karp DR et al. A new type of metal recognition by human T cells: contact residues for peptide-independent bridging of T cell receptor and major histocompatibility complex by nickel. J Exp Med 2003 197 : 1345 53.
26. Amicosante M, Fontenot AP. T-cell recognition in chronic beryllium disease. Clin Immunol 2006 121 : 134 43.
27. Sawyer RT, Day BJ, Fadok VA et al. Beryllium-ferritin: lymphocyte proliferation and macrophage apoptosis in chronic beryllium disease. Am J Respir Cell Mol Biol 2004 31 : 470 7.
28. Chou YK, Edwards DM, Weinberg AD et al. Activation pathways implicate anti-HLA-DP and anti-LFA-1 antibodies as lead candidates for intervention in chronic berylliosis. J Immunol 2005 174 : 4316 24.
29. Farina C, Weber MS, Meinl M, Wekerle H, Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol 2005 4 : 567 75.
30. Ali FR, Larche L. Peptide-based immunotherapy: a novel strategy for allergic disease. Expert Rev Vaccines 2005 4 : 881 9.